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Abstract
A comparison was made between local malaria transmission and malaria imported by travellers to
identify the utility of national and regional annual parasite index (API) in predicting malaria risk and
its value in generating recommendations on malaria prophylaxis for travellers.
Regional malaria transmission data was correlated with malaria acquired in Latin America and
imported into the USA and nine European countries. Between 2000 and 2004, most countries
reported declining malaria transmission. Highest API's in 2003/4 were in Surinam (287.4) Guyana
(209.2) and French Guiana (147.4). The major source of travel associated malaria was Honduras,
French Guiana, Guatemala, Mexico and Ecuador. During 2004 there were 6.3 million visits from
the ten study countries and in 2005, 209 cases of malaria of which 22 (11%) were Plasmodium
falciparum. The risk of adverse events are high and the benefit of avoided benign vivax malaria is
very low under current policy, which may be causing more harm than benefit.
Background
Many public health bodies base their recommendations
for the prevention of malaria in travellers on national sur-
veillance data, which provides information on the inten-
sity and risk of malaria in local populations, expressed as
the annual parasite index (API), which may reflect
regional risks. While this approach appears rational, there
is no evidence that patterns of travel-acquired malaria cor-
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relate with transmission intensity among indigenous pop-
ulations. Recommendations on prophylaxis for travellers
need to balance the threat of malaria, including falci-
parum malaria, and the risk of a fatal outcome, against the
potential toxicity of chemoprophylaxis, a risk which is not
relevant to populations living in endemic regions. Rombo
called into question the use of API to estimate the risk of
travellers acquiring malaria [1]. Highlighting the disparity
between native and traveller's vulnerability and exposure
to infection he has emphasized the need to consider
prophylaxis toxicity when prescribing for travel to low risk
malaria regions.
Providing appropriate malaria prophylaxis advice for trav-
ellers visiting countries in Central and South America can
be complex and challenging, particularly when the jour-
ney involves many regions or countries where multiple
parasite species are present.
This study was set up to review rates of malaria transmis-
sion within Central and South American countries and to
compare these with patterns of imported malaria among
European and US travellers returned from endemic coun-
tries. The aim of the study was to try and identify whether
transmission within a country reflects malaria transmis-
sion among travellers and to examine the usefulness of
API in predicting travellers' risk and its value as a basis for
recommendations of malaria prophylaxis.
Methods
The local population risk is based on reports from the Pan
American Health Organization (PAHO) Regional Office
of the World Health Organization with information on
API provided by countries within the region[2,3]. The
change in the API over the period 1998 and 2004 has been
included to reflect changing trends of malaria transmis-
sion. All countries provide regional and district API data,
and for this study the highest API in each country is used
to represent the maximum risk likely to be faced by trav-
ellers. The malaria risk associated with travel is identified
through reports from National malaria surveillance bod-
ies, describing malaria imported in returned travellers
from Central and South America (Table 1) between the
years 2000 and 2005 (data for 2005 was not available for
France) from nine European countries and the USA (Table
1). Most of this data was provided through and from
members of TropNetEurop, a network of clinical sites,
which have access to national malaria surveillance
reports, and from the literature. Most reports do not con-
tain details on region of travel within countries, and
where several countries have been visited, reports do not
necessarily reflect the country of acquisition. Cases pro-
vided by TropNetEurop were not included in the country
malaria analysis as they would duplicate case reports.
Malaria imported from Mexico was analysed separately
from the Central America region.
The volume of travel will have a significant bearing on the
number of cases of imported malaria and therefore rates,
where possible, were calculated. The World Tourism
Organization collects data on international arrivals and
this data provides an estimate of the number of tourist
departures and arrivals by country. This data was used
where no national statistics were available to estimate the
numbers of visits made from the study countries [4,5]
(Figure 1). Malaria cases recorded in UK travellers were
analysed using a denominator, the number of visits made
by UK citizens to the countries of malaria acquisition.
Data provided by the International Passenger Survey (IPS)
is collected through face-to-face interviews of passengers
at all major ports within the UK. A quarter of a million
passengers are interviewed throughout the year and this
sample provides an estimate of the total annual visits to
each country, the duration of stay and reason for travel.
Malaria cases occurring in United States travellers were
extracted from data published by the Centers for Disease
Control [6-11] and visits made by US citizens to the
region were collected by the USA International Air Travel
Statistics (or I-92) programme. This provides data on out-
bound numbers of US citizens travelling, using point-to-
point air traffic totals from the USA, on departing flights.
Visits to, and malaria from Mexico were analysed sepa-
rately due to the large travelling population from the
USA[12]. Malaria data from France was provided through
Table 1: Regions and Countries from Central and South America 
included in the destination analysis and countries reporting 
imported malaria.
Central America South America
Belize Argentina
Costa Rica Bolivia
El Salvador Brazil
Guatemala Colombia
Honduras Ecuador
Nicaragua French Guiana
Panama Guyana
Paraguay
Mexico Peru
Surinam
Venezuela
C America unspecified S America unspecified
Reported imported Malaria
Czech Republic Finland
France Germany
Holland Norway
Sweden Switzerland
United Kingdom United States of AmericaMalaria Journal 2007, 6:114 http://www.malariajournal.com/content/6/1/114
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a reporting network of 120 selected hospital laboratories
covering approximately half of annual estimates of
malaria cases to the Malaria National Reference Centre
(CNRPalu). French and Dutch denominators were cap-
tured using a methodology similar to that of the USA
International Air Travel Statistics (I-92) programme,
which reflects aircraft coupons capturing passengers
departing to specific destinations between 2000 and
2004. The data on denominators were provided by the
French Aviation Authority and Statistics Netherlands, but
capture methods vary. In the analysis, malaria acquired in
Mexico and visits to Mexico were excluded from the Cen-
tral America groupings.
Results
Malaria risk in Central and South America
Within the region, 21 countries reported malaria trans-
mission [13,3]. An estimated 264 million out of the 867
million inhabitants were at risk of malaria, 11 million of
these at high risk [3]. Between 1998 and 2004 in countries
popular with travellers, Brazil, Peru, Ecuador and Colom-
bia in South America, and Guatemala and Honduras in
Central America, there was a decline in both annual posi-
tive slides and API in high risk regions in all but Colombia
and Honduras (Table 2), and a decline in the absolute
number of cases in all countries except for Peru and
Colombia[14]. The most recent API's ranged from 0.07 to
287 in the highest risk regions. Mexico reported low trans-
mission in two provinces only [3].
Imported malaria
Case reports from Central and South America constitute a
small proportion of total imported malaria. In the USA,
they accounted for 10% of the total imported malaria in
2005, whilst in Europe, in the same year, the proportion
ranged from 1.1% in the UK, 2% (2004) in France, 3.4%
in Switzerland and 2.4% in the Netherlands. By species,
Plasmodium falciparum infections ranged between 3% and
17% of all malaria reports annually from Central America
and between 17% and 24% of cases acquired in South
America. The total number of imported malaria cases
reported to surveillance bodies annually for the years
2000 to 2005 inclusive, fell from 395 to 209 cases of
which 69% were non falciparum in 2005. The bulk of
cases were reported in American travellers, with Guate-
mala and Honduras being the main sources of infection.
Total USA reports fell from 242 to 153 in 2005 of which
84% were non-falciparum, where the species was known.
Six countries reported 10 or less imported malaria cases
from Central and South America in 2005 (Figure 2).
Guatemala, French Guiana and Honduras provided half
(55%) of all imported malaria over the 5 years. French
Guiana was an important source of malaria for French
travellers and Surinam for Dutch travellers. Surinam is a
popular destination for Dutch travellers, (60% of all inter-
national arrivals in 2004 were from the Netherlands [15]
and it is the source of 60% (37% P. falciparum) of all
malaria cases in Dutch travellers from Latin America.
Eighty nine percent of all malaria in French travellers was
acquired in French Guiana, where they make up approxi-
mately two thirds of all tourist arrivals. Seventy percent
were Plasmodium vivax infections and twice as many cases
occurred in civil as in military personnel, although a high
incidence has been reported in the military [16]. The rate
in French residents returned from French Guiana averaged
6.2 per 10,000 visits (P. falciparum 1.3/10,000 and P. vivax
4.3/10,000). Honduras accounted for the largest source of
infection, most were in US travellers (Figure 3) who made
up over a quarter (178,285) of all tourists arrivals in 2004.
Cases from Honduras, predominantly in US travellers
have declined by 20% between 2000 and 2005, despite
the API having increased by 36% in indigenous popula-
tions (Table 2). The rate in Honduras was the highest for
all countries visited by UK travellers (5.6/10,000). There
were five countries (Honduras, Nicaragua, Surinam,
French Guiana and Guatemala) where the rate of malaria
was >1/10,000 visits for UK travellers. Data on the dura-
tion of visit was available for visits by UK travellers, a case
per years travelling (proxy of exposure) was calculated,
based on total nights away, visitors and numbers of cases
of malaria. The average duration of visit by UK travellers
to the South American continent (2005) was 18 days.
Mexico had the lowest risk where one case occurred for
very 22,664 years exposed. The risks for Peru, Columbia
Total visits made by international tourists to the study coun- tries adjusted to visits from the reporting countries Figure 1
Total visits made by international tourists to the study coun-
tries adjusted to visits from the reporting countries.
m1 m2 m3 m4 m5 m6 m7 m
Guyana
Suriname
Paraguay
Bolivia
Venezuela
Colombia
Ecuador
Peru
Argentina
Brazil
Honduras
Nicaragua
Panama
El Salvador
Guatemala
Costa Rica
Millions
South America
All reporting countries 3.4 million
All intl. tourist arrivals 12.6 million
Central America
All reporting countries 1.9 million
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and Brazil were similar, around one case for every 3,000
years exposed, and similar to the risks of UK residents vis-
iting India [17]. Honduras and Guatemala were the high-
est risk countries with one case for every 103 and 513
years exposed respectively.
Low malaria rates were also noted in UK, French and
Dutch visitors to Venezuela, Colombia, Peru and Brazil
during 2004. These four countries received a total 2.6 mil-
lion visitors from the study countries (Figure 1) and had a
maximum incidence of malaria of 2.2 (UK travellers to
Colombia, 2004) per 10,000 visits.
Discussion
This study was designed to identify whether local trans-
mission of malaria within countries of Latin America
reflected the pattern and trends of malaria acquired by
travellers from ten developed countries. During 2004,
twenty one PAHO countries with active malaria programs
examined 6.7 million slides, of which 13% were positive
for malaria, three quarters of them were speciated as P.
vivax infections in an "at risk" population of 262 million
[3]. The detailed information collected in Central and
South American countries and presented by PAHO
[3,2,13] provides evidence of a clear trend of declining
transmission across most of the countries, most notably
in Brazil, which reported a 56% decrease in the high inci-
dence regions, attributed to malaria control programmes
initiated in 2000. The total number of tourists visiting
Latin America is not known precisely, but the World Tour-
ism Organization [4] estimates there were 16 million
international tourist arrivals to South America, with a
16% increase from 2003. Central America, during 2004,
received 5.7 million inbound visitors, a 17% growth in
arrivals over the previous year. The main country sources
of imported malaria were Honduras, French Guiana, Gua-
temala, Mexico and Ecuador, from where there were 1,066
imported cases over five years, accounting for 64% of all
imported cases from Latin America, 75% were non-falci-
parum malaria. There are a number of important limita-
tions that need to be understood when reflecting on the
findings. Local transmission reported to PAHO may be
inconsistent and regions not reporting or not diagnosing
cases may be interpreted as no malaria transmission. The
imported malaria cases collected nationally use different
reporting methods and are of varied quality. The denom-
inators used in the analysis are again of different capture
methods. The USA, France and the Netherlands record the
number of citizens departing to a destination while in the
UK samples of departing passengers are interviewed, cap-
turing destination, duration of travel and reason for travel.
The pattern of travel through the regions by western trav-
Table 2: Numbers of malaria risk regions in popular tourist destinations, reflecting changing incidence, highest risk regions and species 
diagnosed during surveillance
Average API's 
in Moderate 
and High risk 
regions
2004§
Country Highest risk 
regions with 
total 
provinces/
departments‡
2004# 1998 % change API 
1998–2004
Highest regional API 
2004¥
P.F. P.V. Totals P.V.%
Guatemala 4/26 9.6 15.8 -39% 53.68 (Peten Sur 
Occidente)
1,300 28,983 30,283 96%
Honduras 5/9 12.6 9.2 36% 26.55 (Islas de la Bahia) 283 9,033 9,316 97%
Brazil 66/5561 28.0 64.0 -56% 242.05 (Tocantins) 75,685 276,021 351,706 78%
Colombia 18/33 26.2 12.1 116% 233.92 (Cordoba) 42,633 69,272 111,905 62%
Ecuador 12/22 12.0 15.2 -21% 64.43 (Quininde) 5,891 22,839 28,730 79%
French Guiana 5/5 147.4 216.4 -32% 231.27 (Maripasuola) 1,901 752 2,653 28%
Peru 12/34 11.7 21.6 -46% 112.60 (Tumbes) 14,740 74,720 89,460 84%
Surinam 6/10 287.39 263.96 9% 686.07 (Upper 
Saramacca)
12,078 1,494 13,572 11%
Mexico 2/32 0.07 0.44 -84% 0.30 (Oaxaca) 49 3,357 3,406 99%
‡Data for Colombia, Ecuador, French Guiana, Suriname, & Honduras is taken from PAHO Malaria programs in the America (based on 2002 data), 
the remaining data is taken from Malaria programs in the Americas (based on 2004 data).
#Data for Brazil, French Guiana & Surinam is 2003 data
¥Data for Colombia & Suriname is taken from PAHO Malaria programs in the America (based on 2002 data), the remaining data is taken from 
Malaria programs in the Americas (based on 2004 data).
§Data from 2003Malaria Journal 2007, 6:114 http://www.malariajournal.com/content/6/1/114
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ellers is not recorded in the denominator data or through
the malaria case reports, and therefore the proportion vis-
iting high transmission regions are unknown.
Although a number of regions within Peru and Brazil have
an API above 50/1000 cases/year the actual numbers of
malaria cases in returning travellers is low, a total of 145
cases over five years, and in 2005, there were only 30 cases
of which three were P. falciparum. Asymptomatic carriage
in natives living in the Peruvian Amazon near Iquitos is
estimated to be less than 10% and the entomological
inoculation rate for the Amazonas region reported as 10–
20 annually [18]. The small numbers of travel associated
cases from Peru are unlikely to be a result of widespread
use of chemoprophylaxis. Currie and colleagues [19]
examined prophylaxis use in tourists departing Lima,
Peru. Of the 1226 travellers interviewed, 43% were from
the USA. Nearly three quarters had visited only Peru and
54% had visited a malarious region (as defined by CDC).
Of these around half had taken regular chemoprophylaxis
(42% atovaquone/proguanil). During that year (2003)
there were 10 (six P vivax) imported malaria cases from
Peru. The highest numbers of imported malaria cases,
over the 5-year study period, were of P. vivax from Hondu-
ras, Guatemala, Ecuador and French Guiana. Despite an
increase in local transmission in Honduras, total travel
associated cases declined by 20% suggesting that there is
no correlation between the two trends. The rates in US
and UK travellers to the whole region (excluding Mexico)
reveal a similar incidence of 0.3 and 0.8 per 10,000 visits
despite an increasing volume of travel over the study
(237,526 UK and 4.5 million US travellers in 2005).
Mexico had an estimated 20 million visits by US citizens
in 2004. Visits to malaria endemic regions of Mexico are
unknown, but are likely to be small. There was a fall in
Total imported malaria from 9 countries stratified by US and  Non US reporting countries 2000–2005 Figure 3
Total imported malaria from 9 countries stratified by US and 
Non US reporting countries 2000–2005.
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Imported cases by reporting countries 2000–2005. Y axis 1 reflects US and French cases, all other countries are shown against 
Y axis 2.
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imported malaria to the U.S. from Mexico, from 30 case
reports in 2000 to 14 in 2005.
Current chemoprophylaxis policies recommend prophy-
laxis for high risk regions [20-22], but many of these
regions (as shown in Table 2 have a declining risk for
indigenous populations). The inconsistency between
focal high transmission areas in countries popular with
western travellers and small numbers of travel associated
malaria is worth exploring. Significant numbers of travel-
lers may not be using prophylaxis during their travel and
the departure lounge suggests approximately 50% of visi-
tors will be using chemoprophylaxis. Other countries vis-
ited by significant numbers of tourists as reported by WTO
in 2005 – Peru, (1.5 million) Brazil (5.4 million), Guate-
mala (1.3 million) had small numbers of cases and low
rates of malaria. Although these countries have areas of
high transmission, the major parts of these countries have
no malaria transmission. It would appear that most visi-
tors to these countries are at low or no risk of acquiring
infection, whatever their journey and destination within
the country.
Protection against P. vivax, disease despite using the most
widely available regimens is marginal [23-25], as only the
primary attack [23] is aborted. Most clinical episodes
develop some months after infection when travellers have
returned home and are unlikely to be missed through rou-
tine reporting systems. Severe adverse events leading to
stopping medication during chemoprophylactic drug use
were reported in 3–8% of users whilst mild to moderate
adverse events were reported by 32%–45% of users [26].
In the 423,416 visitors from reporting countries to Peru in
2003 [4] approximately 25% (105,000 or 50% of those
visiting a malarious region) visitors were using chemo-
prophylaxis as identified by the airport departure lounge
study [19]. During that year, 10 (two P. falciparum) cases
of malaria were reported in nine study countries after vis-
iting Peru. Using the minimal proportion of users
encountering adverse events from the popular prophy-
laxis regimens [26] an estimated 34,000 travellers would
have suffered an adverse event related to chemoprophy-
laxis use. The risk of adverse events for visitors to Peru and
other regions are likely to be significantly higher than
avoided infections particularly of benign P. vivax malaria
under current policy recommendations. Unless chemo-
prophylaxis prescribing is significantly reduced, current
recommendations are likely to be causing more harm
than benefit.
Policy change
Despite its limitations, this study suggests that the risk of
adverse events from chemoprophylaxis is likely to be sig-
nificantly higher than the risk of acquiring malaria in the
most popular tourist destinations in Central and South
America. Although current national and international
policy focuses on chemoprophylaxis for focal, highly
endemic malaria transmission regions in countries which
have overall low API's, this strategy appears to provide
limited benefit as travellers appear to have a low malaria
attack rate and will acquire P. vivax rather than P. falci-
parum infection. The benefit of chemoprophylaxis in pre-
venting the former is unclear. An alternate strategy
adopted by a number of European countries, for example
Switzerland [27], is to provide travellers with emergency
standby treatment in case of malaria symptoms during
travel. This has the benefit of dealing with a life threaten-
ing attack of falciparum malaria, but avoiding adverse
events associated with excessive chemoprophylaxis. It has
the disadvantage of cost, as all travellers will have to pur-
chase therapy. Two of the highest risk countries reported
by PAHO – French Guiana, and Surinam, correlated to
countries where visitors were at high risk of malaria and
chemoprophylaxis would be appropriate for travel to risk
areas in these countries. There appears to be no clear ben-
efit and significant potential for toxicity in recommending
chemoprophylaxis for visitors to Mexico, where the high-
est API is less than 0.07 for local residents and 20
imported cases annually. Despite the low or falling risk of
malaria, the continued use of bite prevention measures
remains important as these are effective, safe and have the
added benefit of reducing other vector borne diseases.
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